Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Doubel-blinded, Parallel, Active-controlled Phase III Study, to Evaluate the Efficacy and Safety of CMAB807 Treatment Compared with Prolia® in Chinese Postmenopausal Women with Osteoporosis At High Risk of Fracture.

NCT04591275 is registered in ClinicalTrials.gov with Shanghai Biomabs Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT04591275
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04591275 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Doubel-blinded, Parallel, Active-controlled Phase III Study, to Evaluate the Efficacy and Safety of CMAB807 Treatment Compared with Prolia® in Chinese Postmenopausal Women with Osteoporosis At High Risk of Fracture.
Lead sponsor
Shanghai Biomabs Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2021
Completion date
November 1, 2024
Enrollment
278 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

postmenopausal osteoporosis